Marchong Mellone N, Chen Danian, Corson Timothy W, Lee Cheong, Harmandayan Maria, Bowles Ella, Chen Ning, Gallie Brenda L
Division of Cancer Informatics, Room 8-415, Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9.
Mol Cancer Res. 2004 Sep;2(9):495-503.
Retinoblastoma is initiated by loss of both RB1 alleles. Previous studies have shown that retinoblastoma tumors also show further genomic gains and losses. We now define a 2.62 Mbp minimal region of genomic loss of chromosome 16q22, which is likely to contain tumor suppressor gene(s), in 76 retinoblastoma tumors, using loss of heterozygosity (30 of 76 tumors) and quantitative multiplex PCR (71 of 76 tumors). The sequence-tagged site WI-5835 within intron 2 of the cadherin-11 (CDH11) gene showed the highest frequency of loss (54%, 22 of 41 samples tested). A second hotspot for loss (39%, 9 of 23 samples tested) was detected within intron 2 of the cadherin-13 (CDH13) gene. Furthermore, deletion of the exons of CDH11 and/or WI-5835 was shown by quantitative multiplex PCR in 17 of 30 (57%) of previously untested tumors. Immunoblot analyses revealed that 91% (20 of 22) retinoblastoma exhibited either a complete loss or a decrease of the intact form of CDH11 and 8 of 13 showed a prevalent band suggestive of the variant form. Copy number of WI-5835 for these samples correlated with CDH11 protein expression. CDH11 staining was evident in the inner nuclear layer in early mouse retinal development and in small transgenic murine SV40 large T antigen-induced retinoblastoma tumors, but advanced tumors frequently showed loss of CDH11 expression by reverse transcription-PCR, suggestive of a role for CDH11 in tumor progression or metastasis. CDH13 protein and mRNA were consistently expressed in all human and murine retinoblastoma compared with normal adult human retina. Our analyses implicate CDH11, but not CDH13, as a potential tumor suppressor gene in retinoblastoma.
视网膜母细胞瘤由两个RB1等位基因的缺失引发。先前的研究表明,视网膜母细胞瘤肿瘤还表现出进一步的基因组增加和缺失。我们现在使用杂合性缺失(76个肿瘤中的30个)和定量多重PCR(76个肿瘤中的71个),在76个视网膜母细胞瘤肿瘤中定义了一个位于16号染色体q22上的2.62兆碱基对的最小基因组缺失区域,该区域可能包含肿瘤抑制基因。钙黏蛋白-11(CDH11)基因内含子2中的序列标签位点WI-5835显示出最高的缺失频率(54%,41个测试样本中的22个)。在钙黏蛋白-13(CDH13)基因内含子2中检测到第二个缺失热点(39%,23个测试样本中的9个)。此外,通过定量多重PCR在30个先前未测试的肿瘤中的17个(57%)中显示出CDH11和/或WI-5835外显子的缺失。免疫印迹分析显示,91%(22个中的20个)视网膜母细胞瘤表现出CDH11完整形式的完全缺失或减少,13个中的8个显示出一条普遍的条带,提示变体形式。这些样本中WI-5835的拷贝数与CDH11蛋白表达相关。在小鼠视网膜早期发育的内核层以及小型转基因小鼠SV40大T抗原诱导的视网膜母细胞瘤肿瘤中,CDH11染色明显,但晚期肿瘤通过逆转录PCR经常显示出CDH11表达缺失,提示CDH11在肿瘤进展或转移中起作用。与正常成人视网膜相比,CDH13蛋白和mRNA在所有人类和小鼠视网膜母细胞瘤中均持续表达。我们的分析表明,CDH11而非CDH13是视网膜母细胞瘤中潜在的肿瘤抑制基因。